The study enrolled 888 patients who had metabolic risk factors and a baseline or recent liver biopsy showing MASH ... of patients with resolution of steatohepatitis (defined as a score of 0 ...

such as steatohepatitis and hereditary hemochromatosis. Clinicians can then make best use of the information derived from the liver biopsy to help them advise patients on the natural history of ...

Where multiple sensitivity and specificity values are reported, the values providing the highest Youden Index are given (i.e., highest sum of sensitivity and specificity minus one). ALT: Alanine ...

Metabolic dysfunction-associated steatohepatitis (MASH), which used ... It’s often done instead of a liver biopsy. Liver biopsy. Your doctor may perform a liver biopsy to get a sample of ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in ...

Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead product candidate, EFX.

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

If you have obesity, losing even a little weight helps not only improve your overall health, but also prevent liver issues ...